GugliettaLab

We are hiring postdoctoral fellows!!! If you are interested in microbiome, colon cancer and immune responses check this out: nature.com/naturecareers/…

Colorectal cancer is the deadliest cancer for people under 50 #ColorectalCancerAwarenessMonth

Repeated concussions can change the brain over time. New research from MUSC shows that immune activity may play a major role in long term damage after mild traumatic brain injuries. Find out more: tinyurl.com/4e4y4vwe #ChangingWhatsPossible

#RepeatedMildClosedHeadInjury activates complement-driven neuroimmune responses, induces #microglial dysfunction and #neurodegenerative pathways, and post-injury #ComplementInhibition can reverse these effects. @GugliettaLab @MedUnivSC #OpenAccess in #STTT: doi.org/10.1038/s41392…

(2/2) Also, none of this work could have been possible without Dr. Silvia Guglietta (@GugliettaLab), Dr. Stephen Tomlinson, and all the contributing authors. @MUSChealth

🔥📢BIG NEWS! (1/2) I'm excited to share our accepted paper in Nature's Signal Transduction and Targeted Therapy (@sigtrans_sttt) showing a role for complement in repetitive closed head injury. Many thanks to @ResearchMUSC @DeptVetAffairs @NIH @biaamerica nature.com/articles/s4139…

🚨Our team @GugliettaLab @KhalilMallahPhD just published in Signal Transduction & Targeted Therapy: 10.1038/s41392-025-02466-7. Repetitive mild head injury activates brain’s complement system—driving inflammation&memory loss. Complement blockage protects. @MedUnivSC @ResearchMUSC

We performed a multi-omic characterization of the immune landscape in our new model of repetitive traumatic brain injury and identified the mechanisms associated with the protective role of complement inhibition. Great teamwork @GugliettaLab @KhalilMallahPhD @CarstenKriegPhD

4 years in the making and it is finally out in Signal transduction and targeted therapy!!!! nature.com/articles/s4139… @ResearchMUSC @MedUnivSC #braininjury #TBI #Immunology #complement

@humam_kadara @Cancer_Cell @IamLinghua Congratulations! Looking forward to reading it

Very excited to have our work on spatial profiling of lung precursor lesions and invasive lung cancers out in @Cancer_Cell. This work was done in joint collaboration with @IamLinghua and closely with many esteemed groups. Here is a run down of our major findings! We studied multiple cohorts of normal lung tissues, precursor/preinvasive lesions and invasive lung cancer by multiple single-cell and spatial profiling modalities. We first find that invasive lung cancers, naturally, have more complex spatial expression patterns than their premalignant counterparts. Phylogenetic reconstruction using our spatial transcriptomics analysis found that the earliest clones mapped to reactive pneumocytes, the histological resemblant of KRT8+ alveolar cells (KACs)/intermediates! This was super exciting! We previously reported that these transitional cells were not so transitional, they were stuck in limbo and acted as progenitors of lung adenocarcinoma. KACs displayed spatial metaprograms that were distinct from normal alveolar cells and that were closely related to premalignant lesions. Remarkably, KACs had uniquely high expression of 'drivers' of inflammation (IL1R1) and were present in niches that were rich with IL1B high myeloid (macrophages) cells. This epithelial-proinflammatory niche was disease stage-specific. Unlike oncogenic properties which we believe accumulate over the lifetime of the lesion, these niches peaked in early precursor lesions and faded in more advanced stages. We functionally validated these KAC/epithelial-proinflammatory niches in lung carcinogenesis models showing that IL-1b treatment or co-culture with interstitial macrophages act as mitogens for KRT8+ high alveolar cells. Importantly, there is preclinical value (and certainly clinical) value for our findings. We found that targeting IL-1B by neutralizing antibodies, including when combined with PD-1 blockade, was effective in preventing formation of precancerous lesions and their progression to adenocarcinomas. These effects were associated with reduced abundance of KACs! Inflammation appears to be operative in the earliest stages of lung adenocarcinoma development and likely drives oncogenesis of alveolar intermediate cells that function in tissue homeostasis/remodeling after injury. Indeed, it is long thought that tumors are wounds that do not heal, and it is in this healing process if chronic where the budding tumor can hijack inherent properties in the lung. It is also plausible that targeting inflammation is valuable for intercepting lung cancer rather than treating the disease in advanced stages. This supposition is supportive of earlier clinical studies with the IL-1B antibody canakinumab (CANTOS). Very proud of Fuduan Peng joint fellow with the Wang group, now director extraordinaire @Squirrel_PhD, talented student @Yibo_Dai for leading this work, with strong earlier effort from @warapen. I am grateful for collaborations with many groups that I personally learned so much from. This work could not have been done without funding from @NIH @theNCI (NIH funding is important!), @CPRITTexas and @LUNGevity. Also thanks to the astute reviewers as well as the editors @Cancer_Cell who helped us improve our work. #lungcancer #endcancer @MDAndersonNews cell.com/cancer-cell/fu…

Happy to share that our article on the role of the complement system in intestinal inflammation and colon cancer is now published in @jclinicalinvest. Great team work @CarstenKriegPhD and @GugliettaLab

@jasonlukemd @StrandTx Congrats Jason and best of luck with your new role!

Extremely excited for this new opportunity & career challenge! @StrandTx is a field-leader in RNA engineering, lipid nanoparticle technology & now clinical cancer #immunotherapy. Our lead program STX-001 is rapidly advancing with multiple clinical programs coming. Time to work!

@westboundsigned @SDSU Congrats Elena! Exciting news

📣Big news! The Blanco-Suarez Lab is moving to @SDSU in beautiful San Diego!🌅🌴 Excited to rejoin this vibrant science community and continue exploring astrocyte-neuron interactions in stroke and expanding to other models! 🧠Stay tuned for open positions➡️blancosuarezlab.com

@humam_kadara @MDAndersonNews Congrats Humam!

🙏 I am very grateful to be awarded the Elza A. and Ina Shackelford Freeman Endowed Professorship at @MDAndersonNews . Many thanks to trainees, colleagues, mentors, friends and family who continue to inspire me in my journey.

@SGrivennikov I changed the title for my resubmission. The grant was funded. I would say that changing the title in a resubmission is not an issue.

actually, this question never came up before- should I actually keep the title word-to-word of the grant I am REsubmitting or it is perfectly fine to change the title?

This week on Health Focus, Hollings researcher Dr. Silvia Guglietta talks about her work on immunotherapy in colon cancer. Listen on your SC Public Radio station, or check out the website! southcarolinapublicradio.org/show/health-fo…

JCI - Complement-producing maternal microchimeric cells override infection susceptibility in complement-deficient murine offspring jci.org/articles/view/…

Cool work from ⁦@IlievLab⁩ and collaborators: Fungal symbiont transmitted by free-living mice promotes type 2 immunity | Nature idp.nature.com/authorize?resp…

Have you applied for your IMMUNOLOGY2025™️ travel award? Boost your professional development in May! Whether you're with a Laboratory, #Undergrad, #EarlyCareer - apply today: ow.ly/MoAO50U9gwO. #AAI2025 #IMMUNOLOGY2025

Complement factor H is an ICOS ligand modulating Tregs in the glioma microenvironment | Cancer Immunology Research | American Association for Cancer Research aacrjournals.org/cancerimmunolr…

Interested in benchmarking computational methods in computational biology, generally? Save the date, submit an abstract, join us next March in Ascona! Conference website: sites.google.com/view/ascona2025 Please retweet and/or tell your colleagues!